This is an all-cash deal for an upfront consideration of $155 million, and up to an additional $20 million. Janssen will continue to sell the products on behalf of Piramal until the marketing authorisations or relevant business relations are transferred to Piramal. Janssen can earn up to an additional $20 million if the product portfolio achieves certain agreed financial milestones over the next 30 months. Also read: Govt to make screening of oral, cervix and breast cancer mandatory for 30+ from November 2016Commenting on the occasion, Ajay Piramal, Chairman, Piramal Enterprises said, "Healthcare is an important focus area for Piramal Enterprises and we are strongly committed to growing this segment." "This would be our 6th healthcare acquisition in the last two years, inorganically investing Rs 1,800 crores across our healthcare businesses.

Source: India Today October 10, 2016 12:56 UTC